Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by Raymond James

Raymond James upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) to a moderate buy rating in a research report report published on Thursday,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. DA Davidson restated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research note on Monday, December 9th. Finally, StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $78.72 on Thursday. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The firm’s fifty day simple moving average is $79.25 and its 200-day simple moving average is $73.10. The firm has a market capitalization of $3.89 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare has a twelve month low of $57.95 and a twelve month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same period in the prior year, the company posted $1.07 earnings per share. The firm’s quarterly revenue was down .9% compared to the same quarter last year. Equities analysts forecast that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last quarter. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of large investors have recently modified their holdings of PBH. Franklin Resources Inc. raised its stake in shares of Prestige Consumer Healthcare by 4.3% during the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock valued at $1,513,000 after purchasing an additional 894 shares during the period. Sanctuary Advisors LLC grew its holdings in Prestige Consumer Healthcare by 11.0% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock valued at $1,244,000 after purchasing an additional 1,715 shares in the last quarter. Coldstream Capital Management Inc. purchased a new stake in Prestige Consumer Healthcare during the 3rd quarter worth $205,000. Geode Capital Management LLC lifted its holdings in Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after buying an additional 50,961 shares in the last quarter. Finally, M&T Bank Corp boosted its position in Prestige Consumer Healthcare by 23.8% in the 3rd quarter. M&T Bank Corp now owns 4,594 shares of the company’s stock valued at $331,000 after buying an additional 882 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.